Choose what to try for joint soreness

Try home care before a procedure

Shorter walks, supportive shoes, and steady strength work may reduce strain. You don't gain anything by pushing through sharp or worsening soreness.

With physical therapy, you'll build strength through suitable exercises. You'll learn which movements to reduce when the joint gets more sore.

Medicine may provide short-term relief for some people. Your doctor can check whether it's safe with your other medicines.

Give each choice enough time to show a useful change. If sleep or basic movement keeps worsening, arrange an exam.

Compare blood-based care with simpler choices

The name natural pain treatments can mean clinic care made from your blood. Although it uses your blood, the care isn't a home remedy or a promise.

Platelet-rich plasma is blood spun to gather more of its clotting pieces. Compare it with medicine, exercise, and less walking, lifting, or twisting.

Ask when people may first notice relief and when it may fade. You'll also want the total cost and the chance of extra soreness.

Discuss surgery when daily life stays limited

When joint damage is advanced, it may be time to discuss surgery. That conversation doesn't mean you've agreed to an operation.

Knee or hip surgery alternatives are choices considered before an operation. They include exercise or blood-based care, but they don't promise you'll avoid surgery.

People often ask which choice is right. There isn't one answer, so weigh your daily goal, cost, risk, and recovery with your doctor.

Sources

1. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

2. A randomized trial in the New England Journal of Medicine compared physical therapy against intra-articular glucocorticoid injection for knee osteoarthritis and found physical therapy produced better WOMAC outcomes at one year. When a clinic offers an injection, the comparator that matters is not 'nothing' - it is a course of supervised exercise.

   Deyle GD, et al. — Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee.. The New England journal of medicine, 2020. DOI: 10.1056/NEJMoa1905877.

3. In a 2-year RCT, intra-articular triamcinolone given every 12 weeks for knee OA produced significantly GREATER cartilage volume loss than saline, with no significant pain benefit. The most widely used joint injection in medicine is itself associated with structural harm on repeat dosing - relevant context when a clinic frames a biologic as 'the alternative to steroid shots'.

   McAlindon TE, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.

4. MACI (autologous cultured chondrocytes on a porcine collagen membrane, Vericel; STN BL 125603) IS an FDA-LICENSED cell therapy - and its approved indication is narrow and specific: repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects OF THE KNEE, with or without bone involvement, in adults. It is not approved for osteoarthritis. The existence of one licensed cartilage cell therapy for focal defects is the sharpest available way to show what a licensed 'regeneration' product actually looks like, and how far it is from an injection for a worn joint.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — MACI (autologous cultured chondrocytes on porcine collagen membrane). FDA, 2024.

5. The phase II trial of lorecivivint (SM04690), an intra-articular CLK2/DYRK1A inhibitor and Wnt-pathway modulator, is the reference for how a genuine disease-modifying osteoarthritis DRUG is developed - defined molecule, defined target, dose-ranging, radiographic endpoints - which is the standard against which an unstandardised autologous injectate should be read.

   Yazici Y, et al. — Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.. Arthritis & rheumatology (Hoboken, N.J.), 2020. DOI: 10.1002/art.41315.

6. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.